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Compliance and reactivity of the peripheral venous system in chronic
intermittent hemodialysis. A reduced venous compliance and/or inade-
quate venoconstriction could impair hemodynamics during hemodialy-
sis. Therefore, compliance and reactivity of the peripheral venous
system were assessed in hemodialysis patients and controls using strain
gauge plethysmography. Reactivity of the venous system towards an
efferent sympathetic stimulus was assessed using a cold pressor test.
Results showed that venous compliance was reduced in hypertensive
hemodialysis patients compared to normotensive dialysis patients (P
0.0 13) and normotensive controls (P = 0.004). After one dosage with a
directly acting venodilator (nitroglycerin 5 mg sI.) and 3 days of
treatment with an cml-sympathicolytic agent (Doxazosin 2 mg), venous
compliance remained unaltered in hypertensive dialysis patients. Dur-
ing the cold pressor test, the blood pressure response, rise in noradren-
aline levels and decline in venous compliance were normal in hemodi-
alysis patients. However, their response to the Valsalva manoeuver
was significantly impaired (P = 0.01!) compared to healthy controls.
We conclude that hypertension, not renal failure, causes the reduction
of peripheral venous compliance in hemodialysis patients, for which
structural factors might be responsible. Despite the existence of auton-
omous neuropathy, the reaction of the peripheral venous system
towards an efferent sympathetic stimulus is intact in hemodialysis
patients.
Although the venous system plays a pivotal role in blood
pressure regulation [I], few studies have dealt with its structure
and function in hemodialysis patients. The venous system
serves both as a conductance system and as a blood reservoir.
The importance of the latter function is indicated by the fact
that, during normal conditions, about 60% of total blood volume
in the venous system is hemodynamically inactive ('un-
stressed'). Thus, only 40% is hemodynamically active
('stressed') and takes part in the regulation of the circulation
[2]. Compliance is defined as the volume/pressure ratio of the
stressed compartment [3]. In healthy controls, during hemor-
rhage, blood is shifted by passive and active venoconstriction
from the unstressed to the stressed compartments in order to
preserve venous return to the heart [31.
In hemodialysis patients, hypotensive periods frequently
occur and are a cause of major discomfort and sometimes
severe complications during dialysis [4]. Abnormalities of the
venous system could impair blood pressure regulation in two
ways during hemodialysis: either by a reduction in venous
compliance or by inadequate venoconstriction during plasma
volume removal.
A reduction in venous compliance might impair plasma
volume preservation during ultrafiltration and dialysis by inter-
fering with the capillary Starling equilibrium [5]. Moreover,
because of the steep volume/pressure ratio, it could also lead to
a major drop in cardiac filling pressure even when plasma
volume is decreased only slightly [2]. A reduction in venous
compliance in hemodialysis patients was expected because the
relation between the inferior caval vein diameter and right atrial
pressure showed a shift to a higher atrial pressure for a given
caval vein diameter in hemodialysis patients [6, 7] compared
with healthy controls [8, 9]. This indicates an altered pressure!
volume relationship in the venous system of hemodialysis
patients, possibly due to a reduction in compliance. Further-
more, the frequent occurrence of hypertension in the dialysis
population [10], specific factors related to uremia, such as
increased levels of catecholamines [II, 12] and angiotensin II
[13], might also influence the compliance of the venous system.
Inadequate constriction of the venous system during plasma
volume removal could result from uremic autonomous neurop-
athy [141 or from a reduced end-organ sensitivity to the effect of
catecholamines [15].
In this study, the compliance of the peripheral venous system
in hemodialysis patients was assessed the day after dialysis
using strain gauge plethysmography. In order to separate the
effects of hypertension on venous compliance from the effects
of renal failure, normotensive and hypertensive subjects on
hemodialysis was compared with normotensive and hyperten-
sive controls, respectively. Moreover, the reactivity of the
peripheral venous system to an efferent sympathetic stimulus
was assessed and subsequently related to the degree of auton-
omous neuropathy.
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Patient characteristics
Clinically stable patients treated with chronic intermittent
hemodialysis were included. Controls consisted of healthy
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persons and subjects with essential hypertension. Exclusion
criteria were: acute infectious diseases, diabetes mellitus, a
history of shunt operations or the insertion of a central venous
cathether in the side contralateral to the present arterio-venous
shunt (thus reducing the risk of the existence of a central
venous obstruction), previous treatment with ACE inhibitors,
severe coronary or valvular heart disease (NYHA II or more)
and a compromized left ventricular function (ejection fraction
30% or less).
Normotension was defined as a blood pressure below 140/80
mm Hg after hemodialysis for at least six consecutive months
[161, without the use of antihypertensive medication. Hyperten-
sion was defined as a blood pressure higher than 150/90 mm Hg
after hemodialysis without antihypertensive medication, when
patients were normovolemic. Equal limits were applied for
controls. To prevent overlap between the various groups,
subjects with (post-dialytic) blood pressures between 140/80
and 150/90 were excluded.
Patients were dialyzed three times a week at a Gambro
AK-100 or a Fresenius-2008 dialysis apparatus with bicarbonate
as dialysate buffer.
All subjects gave informed consent. The study was approved
by the Ethical Committee of the University Hospital of Maas-
tricht.
Venous compliance
Fifteen normotensive 110 male, 5 female; mean age 50.3
(range 26 to 75) years] and 11 hypertensive [6 male, 5 female;
mean age 53.2 (range 27 to 74) years] dialysis patients, and 14
normotensive [6 male, 8 female; mean age 47,1 (range 35 to 65)
years] and 8 hypertensive [6 male, 2 female; mean age 47 (range
29 to 72) years] controls were studied. Mean time on hemodi-
alysis was 13 (range 3 to 96) months in normotensive patients
and 22 (range 4 to 60) months in hypertensive patients. In the
hypertensive groups, mean duration of hypertension was 7.2
(range 1.5 to 15) years in dialysis patients and 3.9 (range 6 to
7.6) years in controls. All patients had hemoglobin levels > 6.0
mmol/liter. Vasoactive medication was stopped at least six
weeks before the investigation.
In seven hypertensive dialysis patients (4 male, 3 female,
mean age), the effect of treatment with an al-sympathicolytic
agent (Doxazosin) and with a directly acting venodilator (nitro-
glycerin) on venous compliance was assessed.
Venous reactivity
Seven normotensive [4 male, 3 female; mean age 51.6 (range
32 to 66) years], 7 hypertensive [2 male, 5 female; mean age 51.
(range 36 to 74) years] dialysis patients and 7 normotensive (5
male, 2 female; range 36 to 60 years) controls were studied.
Mean time on hemodialysis was 43 (range 8 to 96) months in
normotensive patients and 35 (range 6 to 94) months in hyper-
tensive patients. All patients had hemoglobin levels > 6.0
mmol/Iiter. Two hypertensive patients were treated with a
calcium antagonist (Nifedipine) and one with a p-receptor
antagonist (Metoprolol), which were stopped 14 days before the
study.
Methods
Venous compliance
Venous compliance (VC) was measured by strain gauge
plethysmography [17] (Periflow, Janssen Scientific Instruments,
Beerse, Belgium) with direct intravenous pressure measure-
ments. The investigation was performed in the morning, and, in
dialysis patients, the day after dialysis. Fluid status was as-
sessed by echographic estimation of the inferior caval vein
diameter, corrected for body surface area 16, 71 (vena cava
diameter at normovolemia 8 to 11.5 mm/m2).
All subjects were asked to refrain from smoking, coffee, tea
and sodas during an overnight period. Blood pressure was
measured in supine position after 10 minutes rest (Random-
zero, Hawksley). The study was performed in a temperature
controlled (20 to 23°C) room with the subjects in supine position
and the arm at heart level,
Volume increase was measured using a mercury-filled strain
gauge, applied on the arm contralateral to the arterio-venous
shunt at a distance of one-third of the forearm length from the
lateral epicondyle. A cuff was applied to the upper arm. In the
same arm, a cannula (internal diameter 1 mm; Venflon) was
inserted into an antecubital vein and connected to a pressure
dome (Hewlett-Packard), positioned at right atrium height,
which was considered 5 cm under the sternal angle. Peripheral
venous pressure was measured by a Hewlett-Packard monitor
and graphically displayed. The plethysmograph and pressure
monitor were calibrated. After a stabilization period of 15
minutes, a basal value was obtained.
First, the upper arm cuff was inflated at a cuff pressure of 25
mm Hg and was kept inflated during three minutes. This time
interval was chosen to obtain stabilized values for arm volume
and intravenous pressure. Hereafter, the cuff was deflated for
two minutes to prevent accumulation of interstitial fluid due to
capillary filtration (Fig. 1). The change in arm volume and
intravenous pressure were both measured after cuff deflation,
This was done in order to exclude the effect of capillary
filtration on the obtained volume/pressure ratio. Subsequently,
the cuff was inflated at pressures of 30, 35, 40 and 45 mm Hg.
Again, at each cuff pressure, the cuff was inflated during three
minutes and was deflated during two minutes afterwards,
whereas the volume/pressure ratio was obtained after cuff
deflation (Fig. 1). VC was defined as the slope of the venous
pressure versus arm volume measurements obtained at the
subsequent cuff pressures and was calculated by linear regres-
sion analysis (Fig. 2).
Reproducibility
The coefficient of variation (CV) for intra-day reproducibility
when VC was estimated at different cuff pressures was 8.1%.
When VC was assessed at one cuff pressure the CV was 11.9%.
The CV for inter-day reproducibility was 11.1%. The CV for
inter-observer variability was 0.42%.
Reversibility of a reduction in venous compliance
The reversibility of a reduction in YC was assessed in two
different ways: the possible role of an increased sympathetic
tone was evaluated by treatment during three days with an
al-sympathicolytic agent (Doxazosin 2 mg). Furthermore, the
effect of a single dose on VC of a directly acting venodilator
(nitroglycerin 5 mg si) was assessed.
The effect of Doxazosin was appraised by comparing VC,
measured using the protocol described above, before and after
Doxazosin treatment (3 days later). A treatment of three days
was chosen because this time is necessary to obtain optimal
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Fig. 1. Venous compliance; tracing of a
representative experiment.
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Fig. 2. Example of a calculation of venous compliance by linear
regression analysis. y = 0.21 + 0.058x; r = 0.99; VC = 0.058 mI/I00
mi/mm Hg.
plasma levels because of its relatively long half-life [18]. Blood
pressure before and after Doxazosin treatment was measured
after 30 minutes rest in supine position (Random Zero, Hawk-
sley).
The effect of nitroglycerin on VC was assessed using a
slightly different protocol because of the short duration of
action of nitroglycerin [19].
VC was assessed before and after nitroglycerin administra-
tion at cuff pressures of 30 and 35 mm Hg. The cuff was inflated
at the subsequent cuff pressures during two minutes and de-
flated during the minute after each increment in cuff pressure.
Thirty seconds after nitroglycerin administration, the first cuff
inflation started (Fig. 3). The volume/pressure ratio at each cuff
pressure was assessed after deflation of the arm cuff.
The slope of the volume/pressure curves before and after
nitroglycerin administration were compared to estimate the
effect of nitroglycerin on VC.
Venous reactivity
Reactivity of the peripheral venous system was assessed
using plethysmography together with a cold pressor test, which
stimulates efferent sympathetic activity [20]. Because the he-
modynamic effects of the cold pressor test do not last long [211,
the volume/pressure ratio was only assessed at one cuff pres-
sure (40 mm Hg) before and during the cold pressor test. A cuff
pressure of 40 mm Hg was chosen because capillary filtration is
then still insignificant. A mercury strain gauge, intravenous
cannula and arm cuff were applied to the arm contralateral to
the A-V shunt, as described above. After 40 minutes of rest in
supine position blood samples for the assessment of adrenaline
and noradrenaline (HPLC method: interassay variance <8%)
were taken through the intravenous cannula. Hereafter, the arm
cuff was inflated at a pressure of 40 mm Hg during 80 seconds,
after which the cuff was deflated and a volume/pressure ratio
was obtained. After 15 minutes the cuff was inflated again and
the arm with the A-V shunt was immersed in ice-cold water for
90 seconds (Fig. 4). After 80 seconds immersion, the cuff was
deflated and a volume/pressure ratio obtained. Blood pressure
was recorded continuously (Finapress, TNO [221).
The volume/pressure ratio before and during the cold pressor
test were compared to assess the effect of a sympathetic
stimulus on VC. Both the absolute and relative decline in VC
were expressed. The relative decline (%) was expressed as 100
— (the absolute decline in VC divided by VC before the cold
pressor test).
To estimate total integrity (afferent + efferent part) of the
baroreceptor reflex arc, a Valsalva maneuver was performed by
expiring at a pressure of 40 mm Hg for 15 seconds, while heart
rate was recorded. The response to the maneuver was ex-
pressed as the ratio between the longest R-R interval during the
release phase to the shortest R-R interval during the strain
phase (Valsalva ratio).
Data evaluation
Values are expressed as mean and standard error of the mean
(sEM). Reproducibility was assessed using the coefficient of
variation. Kruskal-Wallis analysis of variance was used to
assess overall differences between the various groups. A Mann-
Whitney signed-rank test was used to evaluate differences
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between specific groups. Differences within groups were eval-
uated using a Wilcoxon rank-sum test. Normal values (90%
confidence limits) for the Valsalva maneuver of O'Brien O'Hare
and Corrall [231 were used to define autonomous neuropathy.
Results
Venous compliance (VC)
The vena cava diameter index was equal in normotensive and
hypertensive dialysis patients (P 0.3; Table 1). Mean arterial
pressure (MAP) was significantly higher in hypertensive pa-
tients and hypertensive controls than in normotensive patients
(P 0.001; P = 0.003, respectively) and controls (P <0.001; P
= 0.001, respectively). VC differed significantly between the
various groups (P = 0.013) and was lower in hypertensive
dialysis patients as compared with normotensive patients (P =
35 FIg. 4. Effect of the cold pressor test on
venous compliance; tracing of a
representative experiment.
0.013) and controls (P 0.004), Peripheral venous pressure did
not differ between the various groups (P = 0,22).
In hypertensive controls, VC did not differ significantly from
norruotensive patients (P = 0.24), normotensive controls (P
0.09) and hypertensive patients (P = 0.13). VC was equal in
normotensive patients and controls (P 0.8).
Reversibility of venous compliance in hypertensive dialysis
patients
The volume status was equal an the investigations before and
after doxazosin treatment (before: VCDI = 7.98 mm/rn2, SEM =
0.33; after: VCDI = 7,38 mm/rn2, SEM = 0.73; P = 0.3). After
Doxazosin treatment, MAP tended to decrease: —3.14mm Hg,
SEM = 1.41; P = 0.07). However, VC remained unaltered
(—0.003 ml/lOO ml mm Hg, SEM = 0.008; P = 0.5). After
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Table 1. Venous compliance
Normotensive
patients
Hypertensive
—__patients
Normotensive
controls
Hypertensive
controls
Number
MAP mm Hg
VC ml/100 mi/mm Hg
PVP mm Hg
VCDI mm/m2
15
90.6 (4.6)'
0.062 (0.005)a
6.7 (0.8)
8.0 (0.5)
11
113.8 (25)b
0041 (Ø005)b
7.0 (0.9)
8.4 (0.6)
14
96.3 (24)b
0.061 (0.003)
4.9 (0.6)
—
8
111.8 (2•1)b.c
0.051 (0.014)
5.0 (0.7)
—
All values are expressed as mean (sEM). Abbreviations are: MAP, mean arterial pressure; VC, venous compliance; PVP, peripheral venous
pressure; and VCDI, vena cava diameter index.
a p < 0.025
b P < 0.01
Compared to normotensive patients
Table 2. Venous reactivity
Normotensive
patients
Hypertensive
patients
Normotensive
controls
Number 7 7 7
MAP mm Hg 80.5 (8.8)" 110.4 (1.9)" 89.8 (2.4)
VC mi/100 0.064 (0.006) 0.049 (0.006)" 0.067 (0.005)
mi/mm Hg
VCDI 7.8 (0.7) 8.1 (0.6) —
mm/m2
Valsalva 1.23 (0.05) 1.25 (0.06)" 1.67 (0.20)""
ratio
NA nmol/ 3.48 (0.40) 3.70 (0.69)" 1.92 (0.17)""
liter
A nmol/iiter 0.72 (0.14) 0.92 (0.28)a 0.29 (0.06)"'
IMAP 21.0 (6.0) 20.6 (3.7) 17.0 (4.7)
mm Hg
i.IVC%
—20.1 (6.l)a —40.2 (6.2)a —21.9 (3.6)
zWCabs
—0.014 (0.002) —0.019 (0.004) —0.012 (0.003)
ml/100 mi/
mm HgNA 0.54 (0.39) 2.10 (0.85) 0.52 (0.18)
nmol/iiter
A nmoi/iiter 0.07 (0.24) 0.12 (0.29) 0.02 (0.06)
All values are expressed as mean (sEM). Abbreviations are: MAP,
mean arterial pressure; MAP, change of MAP during cold pressor test;
VC, venous compliance; VC%, relative change of VC during cold
pressor test; VCDI, vena cava diameter index; VCabs, absolute
change of VC during cold pressor test; NA, basal level of noradrena-
line; zNA, change of NA during cold pressor test; A, basal level of
adrenaline; AA, change of A during cold pressor test.
a < 0.05
b P < 0.025
"P < 0.01
d Compared to normotensive patients
administration of nitroglycerin, arm volume increased initially
during cuff inflation. However, when the cuff was deflated,
basal arm volume returned to a higher level (0.56 ml/100 ml SEM
= 0.12; P = 0.003) with no change in the volume/pressure ratio
(0.005 ml/100 mi/mm Hg; SEM = 0.004; p = 0.4; Fig. 2).
Peripheral venous pressure remained unaltered after nitroglyc-
erin administration.
Venous reactivity
VC, when measured at one cuff pressure, was lower in
hypertensive patients as compared with normotensive controls
(P = 0.03) and tended to be lower in hypertensive patients
compared with normotensive patients (P = 0.08; Table 2).
During the cold pressure test, mean blood pressure rose signif-
icantly in all groups (P = 0.003). The volume/pressure ratio
after cuff deflation decreased significantly (P = 0.0001) in all
groups during the cold pressor test, thus, VC decreased. The
reduction in VC was due to a decrease in arm volume, because
venous pressure remained unaltered.
Relative decline in venous compliance (VC%) during the
cold pressor test was larger in hypertensive patients than in
normotensive patients (P = 0.05) and controls (P = 0.04).
However, the absolute decline in venous compliance (zVCabs)
did not differ significantly between the various groups (P = 0.4).
Also the rise in mean arterial pressure (LMAP) during the cold
pressor test did not differ significantly between the various
groups (P = 0.6). Basal levels of noradrenaline (NA) and
adrenaline (A) were significantly higher in dialysis patients
compared to control subjects (P = 0.03; P = 0.04, respectively).
During the cold pressor test, noradrenaline levels rose in
dialysis patients (P = 0.02) and in controls (P = 0.03), while
adrenaline levels remained stable (LA) in all groups (P = 0.7).
The rise in noradrenaline (NA) was highest in hypertensive
dialysis patients, but did not differ significantly from normoten-
sive dialysis patients (P = 0.11) and controls (P = 0.17). In
hemodialysis patients, no relation was observed between
LWC% (r = 0.04; P = 0.5) and zVCabs (r = 0.03; P = 0.5) and
LNA during the cold pressor test. Also no relation was found
between LMAP and LNA (r = 0.04; P = 0.5).
Six of the 14 dialysis patients (42.9%) had abnormal Valsalva
ratios (corrected for age [11]). In controls the ratios were
normal. Duration of hemodialysis treatment and the Valsalva
ratio were not related significantly (r = 0.23, P 0.3).
The Valsalva ratio was significantly lower in normotensive (P
= 0.02) and hypertensive (P = 0.03) dialysis patients compared
with controls. In hemodialysis patients, no significant relation
was found between zWC% and the Valsalva ratio (r = 0.36; P =
0.11). The relationship between the Valsalva ratio and rise in
MAP (r = 0.23; P = 0.2) and zNA (r = 0.19; P = 0.3) was also
not significant.
Discussion
In this study the compliance and reactivity of the peripheral
venous system in patients treated with chronic intermittent
hemodialysis was assessed by strain gauge plethysmography.
We adopted a slightly modified technique to assess VC:
Peripheral venous pressure was measured directly with intra-
venous pressure measurements and the volume/pressure ratio
was estimated at several cuff pressures after deflation of the arm
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cuff. The arm cuff was deflated after each increment in cuff
pressure, because this reduces the accumulation of interstitial
fluid due to capillary filtration [17]. Assessing VC after deflation
of the arm cuff furthermore excludes the effect of capillary
filtration on the measured volume/pressure ratio [17], an effect
frequently observed at cuff pressures of 45 mm Hg and higher.
A linear volume/pressure relationship was observed in our
study, in contrast to the curvilinear volume/pressure relation
obtained in isolated veins [24]. However, the venous volume!
pressure relationship is only curvilinear below a transmural
pressure of 10 to 15 mm Hg, when the cross-diameter of the
vein is still elliptical [24]. The minimal applied cuff pressure in
the present study was 25 mm Hg, reflecting an intravenous
pressure of 10 to 15 mm Hg. Therefore, venous compliance
was only studied in the linear part of the volume/pressure
relationship which is, however, considered to reflect the true
compliance of the venous wall [25].
Patients and controls were divided into normotensive and
hypertensive groups, respectively. In hemodialysis patients,
postdialytic blood pressure was used to distinguish between
normotensive and hypertensive subjects, because we and oth-
ers have shown by non-invasive interdialytic blood pressure
measurements that the postdialytic blood pressure is a much
better predictor for interdialytic blood pressure than predialytic
blood pressure [16, 26].
VC was clearly reduced in hypertensive dialysis patients,
and, to a lesser degree, in hypertensive controls. No difference
was observed between normotensive controls and normoten-
sive patients. Thus, renal failure and dialysis treatment itself do
not contribute to the reduction of VC in hemodialysis patients.
Our data are at variance with the study of Bradley, Evans and
Cowley [27], who found VC to be reduced in hemodialysis
patients. However, they did not clearly distinguish between
normotensive and hypertensive subjects, which may explain
the difference. Measurements were performed at optimal dry
weight, evaluated by echographic estimation of the inferior
caval vein diameter [6, 7]. Therefore, volume overload as a
possible incriminating factor was excluded. Values for VC in
hypertensive controls did not differ significantly from any
group, which might result from the shorter duration of hyper-
tension in this group as compared to hypertensive dialysis
patients. Another possibility is that VC is reduced to a larger
degree in patients with renal hypertension [28].
The reduced VC in hypertension has been well established [5,
29, 30]. However, the mechanism behind this reduction has not
been completely elucidated. Functional (enhanced sympathetic
activity) and structural factors might play a role. In animals
hypertension has been found to cause structural changes of the
venous wall in resemblance to the changes found in the arterial
wall. Sodium and water logging [31], an increase in the collagen
and elastin amount and smooth muscle-cell hypertrophy [32]
have all been described. The observation that VC in hyperten-
sive dialysis patients did not change after short-term treatment
with an al-sympathicolytic agent or after one dosage with a
directly acting venodilator increases the probability that struc-
tural changes are responsible for the reduction in VC in
hypertensive dialysis patients, That the administered dosage of
doxazosin was too low is not very likely; pharmacokinetics and
effectiveness of doxazosin do not differ between healthy con-
trols and patients with renal failure [18]. Furthermore, blood
pressure tended to decrease during the three day treatment.
After nitroglycerin administration, arm volume increased
during inflation of the arm cuff. However, after deflation the
volume/pressure remained unchanged, whereas the basal arm
volume returned to a higher level (Fig. 3). The explanation is
that nitroglycerin could theoretically exert its action either by
increasing venous compliance or by a venodilatation with an
increase in unstressed volume. As mentioned before, un-
stressed blood volume is the hemodynamically inert part of the
venous system and serves as a blood reservoir [3]. When
nitroglycerin would have caused an increase in compliance, not
only the arm volume after inflation of the arm cuff would have
increased, but so would the volume/pressure ratio after defla-
tion of the arm cuff. Basal arm volume would not have changed
because of rapid flow of the hemodynamically active blood out
of the underarm.
In contrast, with an increase in unstressed volume, the arm
volume increases after inflation of the arm cuff but, after
deflation, returns to a higher basal arm volume without a change
in the volume/pressure ratio. Basal arm volume increases
because the hemodynamically inactive blood remains behind
after release of the arm cuff.
An increase in capillary filtration could also cause an increase
in basal arm volume after cuff deflation. An increased capillary
filtration after nitroglycerin administration is, however, very
unlikely. The dilating action of nitroglycerin is more dominant
on the venous than on the arterial side of the circulation [19].
Thus, it is more likely that hydrostatic pressure over the
capillary wall decreases with a concomitant decrease in capil-
lary filtration. Therefore, nitroglycerin most likely exerts its
effect by an increase in unstressed blood volume with no change
in VC.
Reactivity of the venous system towards a sympathetic
stimulus was assessed with the cold pressor test, which elicits a
response mediated by afferent pain and temperature neurons
and efferent sympathetic vasoconstriction fibers [20], resulting
in a constriction of the blood vessel wall and a rise in blood
pressure. As a measure of the integrity of the complete barore-
ceptor reflex arc and thus of the existence of autonomous
neuropathy, a Valsalva maneuver was used [20]. According to
age-matched reference values [23] 43% of the dialysis patients
demonstrated an abnormal reaction to the Valsalva maneuver.
This abnormal reaction was not related to the duration of
hemodialysis treatment.
During the cold pressor test, VC decreased in all groups,
whereas the relative decline in VC was even increased in
hypertensive dialysis patients. Furthermore, the rise in blood
pressure and catecholamines were equal in hemodialysis pa-
tients and controls. The normal reaction during the cold pressor
test proves that the efferent sympathetic nerves are intact in
hemodialysis patients, which is in accordance with previous
reports [33, 34]. The abnormal response to the Valsalva maneu-
ver suggests a localization of the uremic autonomic defect
either in the afferent part of the baroreptor reflex arc, efferent
parasympathetic nerves or the heart itself. Our data agree with
the results of Bradley et al [35], who found an appropriate
venoconstriction in hemodialysis patients during ultrafiltration,
a condition which stimulates sympathetic activity [36],
In dialysis patients, no relation was found in between the rise
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in blood pressure, the reduction in VC and the rise of noradren-
aline during the cold pressor test. Noradrenaline levels are only
an indirect measure of sympathetic activity, because they only
indicate the amount that is spilled over out of the synaptic cleft
into the blood [37]. Thus, plasma levels of catecholamines do
not necessarily correlate with the local concentration at the
nerve terminal. Adrenaline remained stable because the cold
pressor test does not have a stimulatory effect on the adrenal
medulla, the main production site of adrenaline [20]. Levels of
adrenaline and noradrenaline were increased in dialysis pa-
tients, which is in accordance with previous reports [13]. This
increase might be due to a reduced end-organ sensitivity to the
effect of catecholamines [15]. However, the equal reaction to
the cold pressor test in normotensive dialysis patients and
normotensive controls with respect to blood pressure increase,
decline in VC and rise of noradrenaline levels, do not support
this assumption.
Conclusions
Hypertension and not chronic renal insufficiency leads to a
reduction in venous compliance in patients on hemodialysis,
which is not reversible by short-term intervention with a
directly acting venodilator or an al-sympathicolytic agent.
Despite the existence of autonomous neuropathy in hemodi-
alysis patients, efferent sympathetic stimulation by a cold
pressor test results in a reduction in venous compliance, a rise
in blood pressure response and noradrenaline levels.
The hemodynamic significance during dialysis of the present
findings remain to be elucidated. That efferent sympathetic
stimulation not only results in a venoconstriction but also in a
reduction in venous compliance might increase the hydrostatic
pressure over the capillary wall, and thus impair refill of plasma
volume from the interstitium during plasma volume depletion.
However, the hemodynamic effect of a concomitant venocon-
striction, resulting in the translocation of blood from the un-
stressed to the stressed venous compartments is probably of
more importance in the maintenance of hemodynamic stability
during a decline in plasma volume. Further study is needed to
clarify the role of a reduction of venous compliance in hemo-
dynamics during hemodialysis.
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